Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 215

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Rimal Ilyas, Isla McKerrow Johnson, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede Begna, Abhishek A. Mangaonkar, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M.M. Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2022) 140 (Supplement 1): 1286–1287.

https://doi.org/10.1182/blood-2022-165491

Published: 2022

Journal Articles

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Naseema Gangat, Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al-Kali, Mrinal M.M. Patnaik, Mark R. Litzow, William J. Hogan, Abhishek A. Mangaonkar, Hassan B. Alkhateeb, Mithun V. Shah, Michelle A Elliott, James M. Foran, Talha Badar, Jeanne M. Palmer, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9675–9676.

https://doi.org/10.1182/blood-2022-163485

Published: 2022

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

https://doi.org/10.1182/blood-2022-163518

Published: 2022

Journal Articles

CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients

Rimal Ilyas, Kristen McCullough, Talha Badar, Mrinal M.M. Patnaik, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2022) 140 (Supplement 1): 9704–9705.

https://doi.org/10.1182/blood-2022-160222

Published: 2022

Journal Articles

Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013

Naseema Gangat, Kebede H. Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Animesh Pardanani, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 3945–3946.

https://doi.org/10.1182/blood-2022-160179

Published: 2022

Journal Articles

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Isla McKerrow Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede Begna, Abhishek A. Mangaonkar, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2022) 140 (Supplement 1): 3233–3234.

https://doi.org/10.1182/blood-2022-167967

Published: 2022

Journal Articles

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Maymona Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Abhishek A. Mangaonkar, Mrinal M.M. Patnaik, Michelle A Elliott, Hassan B. Alkhateeb, Min Shi, Matthew Howard, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9735–9736.

https://doi.org/10.1182/blood-2022-163450

Published: 2022

Journal Articles

Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

John McGlothlin, Jithma P. Abeykoon, Eyad Al-Hattab, Aneel A. Ashrani, Michelle A Elliott, Ronald Go, C. Christopher Hook, Animesh Pardanani, Rajiv K. Pruthi, Meera Sridharan, Alexandra P. Wolanskyj

Blood (2022) 140 (Supplement 1): 5328–5330.

https://doi.org/10.1182/blood-2022-159270

Published: 2022

Journal Articles

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Animesh Pardanani, Ayalew Tefferi, Amritpal Singh, Aref Al-Kali, Mrinal M. Patnaik, William J. Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen

Blood (2022) 140 (Supplement 1): 6872–6873.

https://doi.org/10.1182/blood-2022-167720

Published: 2022

Journal Articles

JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy

Naseema Gangat, Natasha Szuber, Hassan Alkhateeb, Aref Al-Kali, Animesh Pardanani, Ayalew Tefferi

Blood (2021) 138 (26): 2886–2889.

https://doi.org/10.1182/blood.2021013996

Published: 2021

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy

Kebede H. Begna, Mithun V. Shah, Naseema Gangat, Hassan B. Alkhateeb, Mrinal M. Patnaik, Aref Al-Kali, Michelle A. Elliot, William J Hogan, Mark R. Litzow, C. Christopher Hook, Abhishek A. Mangaonkar, Rong He, Dong Chen, Animesh Pardanani, Rhett P. Ketterling, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2021-145745

Published: 2021

Journal Articles

High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases

Naseema Gangat, Jennifer L Oliveira, James D Hoyer, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2021-153956

Published: 2021

Journal Articles

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Abdulraheem Yacoub, Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Vikas Gupta, Sangmin Lee, Gary J. Schiller, Minakshi S. Taparia, Animesh Pardanani, Ayalew Tefferi, Srdan Verstovsek, Joseph D. Khoury, Christopher L Brooks, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 140.

https://doi.org/10.1182/blood-2021-145276

Published: 2021

Journal Articles

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-134963

Published: 2020

Journal Articles

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Haris Ali, MD, Abdulraheem Yacoub, MD, Eunice S. Wang, MD, Sangmin Lee, MD, Gary J. Schiller, MD, Christopher Brooks, PhD, Nicole Rupprecht, MS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Moshe Talpaz, MD, Minakshi S. Taparia, MBBS, Tariq I. Mughal, MD FRCP, Srdan Verstovsek, MD PhD, Joseph D. Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137572

Published: 2020

Journal Articles

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Gordon Ruan, MD, Caleb J. Smith, MD, Courtney Day, William Harmsen, Abhishek A. Mangaonkar, MBBS, Hassan B. Alkhateeb, MD, Kebede H. Begna, MD, Aref Al-Kali, MD, Mark Litzow, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Michelle A Elliott, MD, Ayalew Tefferi, MD, Ronald S. Go, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136350

Published: 2020

Journal Articles

Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139050

Published: 2020

Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-137279

Published: 2020

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients

Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy

High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only